We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SEER:NASDAQSeer, Inc. Analysis

Data as of 2026-08-02 - not real-time

$2.22

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Seer, Inc. trades at $2.22, comfortably above its 20‑day SMA (2.12) and the 50‑day SMA (1.90) but still below the 200‑day SMA (1.91), suggesting short‑term momentum without a clear long‑term trend. The RSI of 63 shows modest buying pressure, while the MACD histogram has turned negative, flagging bearish momentum. Volatility is extreme at ~99% over 30 days and beta sits above 1.5, indicating the stock moves sharply with the market. Fundamentals are weak – negative earnings, operating loss of ~‑6%, and a forward PE of –2.27 – yet the price‑to‑book of 0.51 and cash‑to‑market‑cap ratio (>1.3) imply a discount relative to net assets. The most material catalyst is the unsolicited acquisition proposal from CEO Omid Farokhzad at $2.45 per share plus contingent value rights, which could provide a modest premium if approved.
Given the high technical volatility, a cash‑rich balance sheet, and the pending shareholder vote on board nominations, the near‑term outlook hinges on whether the proposal gains traction. Absent a confirmed deal, the stock remains a high‑risk, value‑oriented play with limited upside beyond the proposed $2.45 price.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Unsolicited acquisition proposal offering a $2.45 per share premium
  • Technical support near $1.82 and price above short‑term moving averages
  • Strong cash position relative to market cap

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Uncertainty around shareholder approval and board composition
  • Continued negative operating cash flow and earnings
  • High volatility and beta suggesting price swings

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Fundamental deficits (negative margins, high debt‑to‑equity)
  • Biotech sector's regulatory and execution risk
  • Potential for value realization only if acquisition closes or profitability improves

Key Metrics & Analysis

Financial Health

Revenue Growth-33.60%
P/E Ratio-2.3
ROE-25.52%
ROA-15.04%
Debt/Equity9.54
P/B Ratio0.5
Op. Cash Flow$-48466000
Free Cash Flow$-31675124
Industry P/E29.2

Technical Analysis

TrendNeutral
RSI63.0
Support$1.82
Resistance$2.34
MA 20$2.12
MA 50$1.90
MA 200$1.91
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Target Price$4.00
Upside/Downside80.18%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.04
Volatility99.17%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.